Indivior (INDV)

Sector:

Pharma and Biotech

Index:

FTSE 250

789.50p
   
  • Change Today:
    -2.50p
  • 52 Week High: 1,764.00p
  • 52 Week Low: 576.50p
  • Currency: UK Pounds
  • Shares Issued: 127.14m
  • Volume: 759,828
  • Market Cap: £1,003.75m
  • RiskGrade: 314
  • Beta: 1.50

Indivior CUD study fails to meet primary and secondary endpoints

By Iain Gilbert

Date: Wednesday 04 Sep 2024

LONDON (ShareCast) - (Sharecast News) - Drugmaker Indivior said on Wednesday that the primary and secondary endpoints of Aelis Farma's clinical Phase 2B study of AEF0117 use in participants with cannabis use disorder had not been met.
Indivior said the purpose of the trial was twofold - to show that AEF0117 lowers cannabis use and to determine the endpoints and optimal dosage of AEF0117 for use in future studies.

However, the London-listed group stated the results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to less than one day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used less than two days per week, were not met.

"Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD," said Indivior.

"Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favourable clinical data, Indivior does not currently expect to exercise its option."

As of 0850 BST, Indivior shares were down 1.86% at 896.0p.









Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Indivior Market Data

Currency UK Pounds
Share Price 789.50p
Change Today -2.50p
% Change -0.32 %
52 Week High 1,764.00p
52 Week Low 576.50p
Volume 759,828
Shares Issued 127.14m
Market Cap £1,003.75m
Beta 1.50
RiskGrade 314

Indivior Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.56% below the market average55.56% below the market average55.56% below the market average55.56% below the market average55.56% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Price Trend
66.85% above the market average66.85% above the market average66.85% above the market average66.85% above the market average66.85% above the market average
59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average
Income Not Available
Growth
54.17% above the market average54.17% above the market average54.17% above the market average54.17% above the market average54.17% above the market average
Sector averageSector averageSector averageSector averageSector average

What The Brokers Say

Strong Buy 2
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Indivior Dividends

No dividends found

Trades for 08-Nov-2024

Time Volume / Share Price
16:38 495 @ 789.50p
16:35 20,526 @ 789.50p
16:35 249,285 @ 789.50p
16:35 144 @ 789.50p
16:35 1,193 @ 789.50p

Indivior Key Personnel

CEO Mark Crossley
Chair Graham Hetherington

Top of Page